ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

(marketscreener.com) -- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 -- ChemoCentryx, Inc., , today announced two upcoming poster presentations for CCX559, the Company’s...https://www.marketscreener.com/quote/stock/CHEMOCENTRYX-INC-9978217/news/ChemoCentryx-Announces-Upcoming-Presentations-for-Orally-Administered-PD-L1-Inhibitor-CCX559-at-th-41933231/?utm_medium=RSS&utm_content=20221005